The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Mavik is an angiotensin converting enzyme (ACE) inhibitor
indicated for the treatment of hypertension when used alone or in
combination with other antihypertensive medication, such as
hydrochlorothiazide. Knoll Pharmaceutical Company expects to make
Mavik available by prescription in one mg, two mg, and four mg
dosage strengths. In Afro-American subjects, the minimal effective
daily dose is two mg (versus one mg in Caucasians).
In clinical studies, Mavik was shown to provide excellent
24-hour blood pressure control when taken once daily.
Mavik was well tolerated in clinical trials. The most common
side effects were cough (1.9%), dizziness (1.3%), and diarrhea
(1.0%). Headache and fatigue occurred in less than 1% of patients,
but were reported more often on placebo. Mavik is contraindicated
in subjects who are hypersensitive to the product. Angiodema has
been reported in subjects receiving ACE inhibitors.
The clinical significance of tissue ACE inhibition has not been